Kinaxo To Analyze Protein PTMs for Boehringer Ingelheim

Oct 13, 2008

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies said today that it will use its mass spectrometry platform to quantitatively analyze post-translational modifications of proteins for Boehringer Ingelheim.

Kinaxo, a spinout of the Max-Planck Institute of Biochemistry based in Martinsried, Germany, will use its Cellular Target Profiling technology to study the effects of different compounds on proteome-wide signal transduction pathways for the drugmaker.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Edited Oil in Use

Oil made from gene-edited soybeans is already in use, according to the Associated Press.

PGx Philanthropy

USA Today reports that Department of Veterans Affairs is teaming up with Sanford Health to provide veterans with genetic testing.

"Wild West"

Mother Jones reports there are few regulations overseeing the use of genetic genealogy by law enforcement.

This Week in Science

In Science this week: analysis of ancient DNA recovered from Iberian populations, and more.

Featured White Papers

AlbuVoid Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II

Stroma Liquid Biopsy, a pan-cancer biomarker panel of dysregulation derived from blood

Lipid Removal Sample Prep for Cell Response Applications

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Apr

17

Featured Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

Menu